Merits of Level III Axillary Dissection in Node-Positive Breast Cancer: A Prospective, Single-Institution Study From India

Shalaka Joshi, MCh, MRes1; Jarin Noronha, MCh1; Rohini Hawaldar, BSC, DCM1; Girish Kundgulwar, MCh1; Vaibhav Vamnali, B Com PDCR1; Vani Parmar, MS1; Nita Nair, MCh1; Tanuja Shet, MD1; and Rajendra Badwe, MS1

Abstract

Purpose A complete axillary lymph node (ALN) dissection is therapeutic in node-positive breast cancer. Presently, there is no international consensus regarding anatomic levels to be addressed in complete axillary dissection. We assessed the burden of disease in level III axilla.

Materials and Methods A prospectively maintained database was assessed for 1,591 consecutive patients with nonmetastatic breast cancer registered at Tata Memorial Center, Mumbai, between January 2009 and December 2014.

Results A median of four (zero to 20) level III ALNs were dissected and a median of two (one to 17) nodes were positive. A total of 27.3% (434 of 1,591) patients had level III ALN metastasis, and 4.7% of patients had positive interpectoral nodes. Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. A total of 9.4% of patients had level III involvement when one to three ALNs were positive in level I and II (P < .001). Some 53.2% of patients had level III metastases in the presence of four or more positive level I and II ALNs. On logistic regression analysis, four or more positive ALNs in level I or II (P < .001), inner/central quadrant tumor location (P = .013), and perinodal extension (P < .001) were associated with level III ALN involvement. At a median follow-up of 36 months, the disease-free survival was significantly worse for level III ALN metastases on univariate analysis (P < .001). On multivariate Cox regression analysis, histologic grade (P = .006), four or more positive ALNs (P < .001), hormone receptor status (P < .001), and tumor size (P = .037) were independent prognostic factors for disease-free survival.

Conclusion The axillary nodal burden is high in patients with breast cancer in developing countries like India. One of two women with four or more positive level I and II ALNs may have residual disease in level III if it is not cleared during surgery. Intraoperative interpectoral space clearance should be considered in the presence of either palpable interpectoral lymph nodes or multiple positive ALNs.

J Global Oncol. © 2019 by American Society of Clinical Oncology

Introduction

Surgery is the mainstay of treatment of nonmetastatic breast cancer. Mastectomy and breast conservation surgery are proven to have equivalent outcomes in carefully selected patients. It is necessary to stage the axilla for planning appropriate adjuvant treatment. A complete axillary dissection is usually carried out in most node-positive cases. A clinicoradiologically node-negative axilla still has a 30% to 40% possibility of harboring occult metastatic disease. A sentinel node biopsy or low axillary sampling is necessary to stage the axilla in clinically node-negative cases. In the event of negative axillary lymph nodes (ALNs) on SNB or axillary sampling, one can forgo a complete axillary dissection, with an acceptable false-negative rate of 10%. Limiting the extent of axillary dissection significantly reduces the morbidity in node-negative patients. The current practice is to complete axillary dissection in the presence of clinically positive ALNs or positive sentinel nodes. Recently, the ACOSOG Z11 study demonstrated that observing the axilla is noninferior to a standard axillary dissection, even in the presence of one to three positive ALNs. In addition, the After Mapping of the Axilla Radiotherapy or Surgery (AMAROS) study has also shown axillary irradiation to be noninferior to axillary dissection. Both studies predominantly included a group of low-risk, postmenopausal hormone-sensitive patients with inherent good prognosis. Therefore, the applicability of these studies in the Indian scenario is questionable, because only a small proportion of our patients fit the criteria where a complete axillary dissection can be avoided. Anatomically, the axillary space is divided into three levels by the pectoralis minor muscle. The dissection...
of level III ALNs, located between the costoclavicular ligament of Halsted and the medial border of pectoralis minor, is associated with a slightly longer surgical time and associated morbidity. There is no international consensus on the anatomic levels of axilla to be addressed as a part of routine axillary dissection. National Comprehensive Cancer Network guidelines recommend to clear level I and II of the axilla only. Our institutional policy is to complete the axillary dissection up to level III in all patients with proven positive axillary nodes. The objective of this study was to determine the extent of level III ALN involvement and to ascertain the merits of doing a level III ALN dissection.

**MATERIALS AND METHODS**

We reviewed our prospectively maintained database of 1,591 consecutive patients with nonmetastatic breast cancer who underwent up-front surgery at a single high-volume, tertiary care oncology institution, Tata Memorial Center, between January 2009 and December 2014. Patients were evaluated by a multidisciplinary team and underwent mastectomy or breast conservation surgery on the basis of patient choice and disease characteristics. Axillary levels I, II, and III were dissected and sent for pathologic evaluation separately. Details of their histopathological records were retrieved from the electronic medical records.

**Axillary Dissection**

Patients with clinicoradiologic positive ALNs or positive nodes on axillary sampling (as determined on frozen section or final histopathology reporting) underwent removal of level I to III ALNs up to the costoclavicular ligament of Halsted. Interpectoral nodes were removed separately. The apical or level III ALNs were addressed via an interpectoral approach by identifying the space

---

**TABLE 1. Clinicopathologic Features of the Node-Positive Patients (N = 1,591)**

| Clinicopathologic Characteristic | Measure |
|---------------------------------|---------|
| Average age, years (range)      | 50 (22-91) |
| Histologic type                 |         |
| Invasive ductal carcinoma       | 1,558 (98) |
| Others                          | 33 (2)   |
| Histologic grade (MRB)          |         |
| I/II                            | 301 (18.9) |
| III                             | 1,279 (80.4) |
| Not known*                      | 11 (0.7)  |
| pT size                         |         |
| < 5 cm                          | 1,414 (88.9) |
| > 5 cm                          | 143 (9.0)  |
| Not known*                      | 34 (2.1)   |
| Median, cm                      | 3        |
| Mean, cm                        | 3.2      |
| Tumor quadrant                  |         |
| Outer                           | 780 (49)  |
| Inner                           | 314 (19.7) |
| Central                         | 329 (20.7) |
| Multicentric                    | 104 (6.5)  |
| Axilla only                      | 7 (0.4)   |
| Not known*                      | 57 (3.6)  |
| Hormone receptor status (ER and/or PR) |       |
| Positive                        | 1,071 (67.3) |
| Negative                        | 485 (30.5)  |
| Not known*                      | 35 (2.2)   |
| HER2 status (IHC or FISH in case of equivocal IHC) | |
| Positive                        | 343 (21.6)  |
| Negative                        | 1,015 (63.8) |
| Equivocal                       | 229 (14.4)  |
| Not known*                      | 4 (0.3)    |
| Type of surgery                 |         |
| Breast conservation surgery     | 702 (44.1)  |
| Modified radical mastectomy     | 889 (55.9)  |
| Lymph nodal status              |         |
| N1                               | 897 (56.4)  |
| N2                               | 425 (26.7)  |
| N3                               | 269 (16.9)  |
| Perinodal extension             |         |
| Present                         | 1,196 (78.2) |
| Absent                          | 334 (21)   |
| Not known*                      | 61 (3.8)   |
| Lymphovascular emboli           | Present  | 521 (32.7)  |

(Continued in next column)
between pectoralis major and minor muscles and retracting the pectoralis minor muscle laterally or by a subpectoral approach.

**Statistical Analysis**

Baseline clinicopathologic factors of the cohort were reported as numbers and percentage. Univariate analysis was performed using Pearson chi-square or Fisher’s exact test to look for association between level III ALN metastases and other categorical variables. Multivariate analysis was done by logistic regression to identify independent predictors of level III ALN involvement. A receiver operating characteristic curve was plotted to identify the number of ALNs in level I and II to predict level III involvement. The disease-free survival (DFS) was estimated using a Kaplan-Meier curve. The log-rank (Mantel-Cox) test was used to study the impact of prognostic factors on DFS. Multivariate Cox regression analysis was carried out to study the independent prognostic factors affecting DFS. A test was statistically significant if the two-sided \( P \) value was \( \leq .05 \).

Data were analyzed using SPSS version 21.0 (IBM, Armonk, NY) for Windows.

**RESULTS**

In our series of 1,591 patients, 889 patients (55.9%) underwent modified radical mastectomy and 702 (44.1%) underwent breast conservation surgery. A total of 98% of patients had infiltrating ductal carcinoma, and 80.4% had grade III tumors. The mean tumor size was 3.2 cm. The tumors were located in the outer quadrant (780 [49%]), inner quadrant (314 [19.7%]), and central/multicentric (433 [27.2%]). A total of 67.3% were hormone-sensitive tumors (estrogen receptor and/or progesterone receptor positive), and 21.6% were human epidermal growth factor receptor 2 positive.

All patients had positive ALNs, with 897 patients (56.4%) having one to three node–positive and 694 (43.6%) having four or more node–positive ALNs. The median total ALNs harvested was 19 (three to 74), of which a median of three (one to 43) ALNs were positive. The details of clinicopathologic characteristics and other demographic features are listed in Table 1. In level I and II axillary nodes, 933 patients (58.6%) had one to three positive nodes, and 648 (40.7%) had four or more positive nodes. Ten patients (0.7%) had skip involvement of level III, with negative level I and II ALNs. Level III ALNs were positive in 27.3% (434 of 1,591) of the patients. A median of four (zero to 20) ALNs were harvested in level III, and a median of two (one to 17) were positive with disease involvement.

**Interpectoral Lymph Node Status**

In 52.3% (835 of 1,591) of patients, an interpectoral lymph node dissection was carried out separately. In 104 (12.4%) of these 835 patients, a lymph node was identified on histopathology, while the others had only fibrofatty tissue. Forty (38.4%) of the 104 interpectoral lymph nodes were metastatic. Thus, the overall rate of interpectoral lymph node involvement was 4.7% (40 of 835).

**Predicting Level III Positivity**

We plotted a receiver operating characteristic curve to identify the number of positive level I and II ALNs that best predicted level III ALN metastases (Fig 1). At a cutoff of 3.5 LNs, the sensitivity, specificity, and positive and negative predictive values for apical ALN positivity were 79.5%, 73.8%, 53%, and 91% (Table 2). For practical purpose, we took the lymph node cutoff as four (instead of 3.5) for all further analyses. When four or more ALNs were positive in level I and II, apical ALN metastasis was seen in 53.2% (345 of 648) of patients, whereas only 9.4% (89 of 943) of patients had positive level III ALNs when one to three ALNs were involved in level I and II.

On univariate analysis (\( \chi^2/Fisher’s \) exact test), tumor size greater than 5 cm \( (P = .024) \), histologic grade III \( (P = .034) \), human epidermal growth factor receptor 2–positive status \( (P = 0.007) \), inner/central tumor quadrant location \( (P = 0.002) \), four or more positive ALNs in level I/II \( (P < .001) \), presence of perinodal extension (PNE; \( P < .001) \), and presence of lymphovascular space invasion (LVI; \( P < .001) \)
were significantly associated with level III ALN metastases. Age, histologic grade, and hormone receptor status did not correlate significantly with level III involvement (Table 3).

On logistic regression analysis, four or more positive ALNs in level I and II (odds ratio [OR], 7.88; 95% CI, 5.70 to 10.88; \( P < .001 \)), inner/central quadrant tumor location (OR, 1.46; 95% CI, 1.07 to 1.98; \( P = .013 \)), and PNE (OR, 4.63; 95% CI, 2.46 to 8.70; \( P < .001 \)) along with LVI (OR, 1.47; 95% CI, 1.08 to 2.00; \( P = .015 \)) were other clinicopathologic features significantly associated with level III ALN positivity (Table 3).

**Survival Analysis**

At a median follow-up of 36 months, DFS was significantly worse for patients with level III ALN involvement (76% vs 87.1% in patients with no level III ALN metastases; \( P < .001 \); Fig 2). On univariate analysis, all factors except age and tumor quadrant had a significant impact on DFS (Table 4). On a multivariate Cox regression analysis, histologic grade (hazard ratio [HR], 2.12; 95% CI, 1.24 to 3.64; \( P = .006 \)), four or more positive ALNs (HR, 2.02; 95% CI, 1.41 to 2.90; \( P < .001 \)), hormone receptor status (HR, 1.82; 95% CI, 1.32 to 2.49; \( P < .001 \)), and tumor size (HR, 0.62; 95% CI, 0.40 to 0.97; \( P = .037 \)) were independent prognostic factors for DFS. Level III involvement was not an independent poor prognostic factor (HR, 1.30; 95% CI, 0.92 to 1.85; \( P = .138 \)) in the multivariate analysis.

**DISCUSSION**

Breast cancer surgery has seen a gradual transition from radical mastectomy to breast conservation.10,11 Over time, surgical management of the axilla has also seen a conservative shift from complete axillary dissection to sentinel node biopsy.3,12 In Milan, a mathematical model

### TABLE 3. Univariate and Multivariate Analysis of Clinicopathologic Factors Predicting Level III ALN Positivity

| Category                   | Univariate (chi square/Fisher's exact) | Logistic Regression, Multivariate |
|----------------------------|---------------------------------------|----------------------------------|
|                           | Level III Positive ALN                | **P**                            |
| Age, years                 |                                       | **OR** 95% CI **P**               |
| < 50                       | 215 of 815                            | .43                              |
| > 50                       | 219 of 776                            | 1.155 0.851 to 1.568 .354         |
| Tumor size, cm             |                                       | **P**                            |
| < 5                        | 376 of 1,038                          | .024                             |
| ≥ 5                        | 51 of 143                             | 1.156 0.894 to 1.494 .268         |
| Histologic grade           |                                       | **P**                            |
| Grade 1, 2                 | 72 of 229                             | .034                             |
| Grade 3                    | 359 of 920                            | 1.221 0.794 to 1.877 .363         |
| Tumor quadrant             |                                       | **P**                            |
| Outer                      | 180 of 761                            | .002                             |
| Inner, central             | 226 of 730                            | 1.458 1.075 to 1.978 .015         |
| No. of positive level I or II ALNs |                       |                                  |
| < 4                        | 89 of 943                             | < .001                           |
| ≥ 4                        | 345 of 648                            | 7.877 5.703 to 10.879 < .001      |
| HER2 status                |                                       | **P**                            |
| Positive                   | 118 of 343                            | .001                             |
| Negative                   | 255 of 1,015                          | 1.514 1.062 to 2.158 .022         |
| HR (ER and/or PR) status   |                                       | **P**                            |
| Positive                   | 293 of 1,071                          | 1.00                             |
| Negative                   | 133 of 485                            | 0.957 0.677 to 1.352 .802         |
| PNE                        |                                       | **P**                            |
| Present                    | 412 of 1,196                          | < .001                           |
| Absent                     | 15 of 334                             | 4.626 2.458 to 8.705 < .001       |
| LVI                        |                                       | **P**                            |
| Present                    | 194                                   | < .001                           |
| Absent                     | 229                                   | 1.472 1.079 to 2.006 .015         |

Abbreviations: ALN, axillary lymph node; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; LVI, lymphovascular invasion; OR, odds ratio; PNE, perinodal extension; PR, progesterone receptor.
constructed using 1,446 patients’ data predicted that to not leave behind residual disease in 90% of patients, a minimum of 10 ALNs had to be dissected.13 Hence, in the TNM staging, a minimum of 10 ALNs were believed to be essential for accurate staging of axilla. Clinical examination of the axilla is notoriously inaccurate in staging, with a 30% false-positive rate and a 45% false-negative rate.14 In the absence of metastases in a sentinel lymph node biopsy or low axillary sampling, avoiding complete axillary dissection is now accepted as the standard of care.3 There are fewer adverse effects with sentinel node biopsy as compared with complete axillary dissection in a node-negative axilla.3,5,15,16 The widely acceptable false-negative rate of 10% has not led to a detriment in overall survival in randomized controlled trials.3,4 It should be noted that the absolute number of axillary recurrences, albeit small, doubled in the no axillary dissection arm in the NSABP (National Surgical Adjuvant Breast and Bowel Project) B-32 study.3 We routinely carry out low axillary sampling in node-negative axilla, a procedure similar in principle to sentinel node biopsy, with a proven comparable false-negative rate.2 ALN metastasis is considered the most important prognostic factor for early breast cancer, and the prognosis worsens as the number of positive lymph nodes increases.17 The therapeutic role of axillary dissection has been questioned by many, and some authors have labeled it as only a staging procedure for prognostication and planning appropriate adjuvant therapy.13 NSABP B-04 was the first randomized study that reported no survival advantage with axillary dissection.18 However, the axillary recurrence rate in the no axillary treatment arm was 19%. A number of other studies have suggested better local control with complete axillary dissection, which amounts to an improvement in survival.19,20 The Early Breast Cancer Trialists’ Collaborative Group has reported one life saved for every four local recurrences avoided.21 The therapeutic advantage of complete axillary dissection in breast cancer has been proven for node-positive patients.22 In a Bayesian meta-analysis of six randomized controlled trials, prophylactic axillary lymph node dissection had an average overall survival benefit of 5.4% (95% CI, 2.7% to 8.0%; probability of survival benefit > 99.5%).20 In patients with a positive sentinel node, the American Society of Clinical Oncology does recommend a complete axillary lymph node dissection.23 The National Comprehensive Cancer Network recommends routine level I clearance and palpation of level II and III for presence of nodes.6 In a recent Cochrane review, treatment with less axillary surgery (sentinel node biopsy or axillary sampling) was associated with a reduced overall survival as compared with a complete axillary lymph node dissection (HR, 1.09; 95% CI, 1.01 to 1.17; 18 studies; 6,478 patients).24 They concluded that limited axillary surgery is acceptable only in pathologically proven node-negative axilla.

In our analysis, we found a high incidence of level III ALN involvement (ie, 27.3% of all node-positive patients). The probability of positive level III ALNs was as high as 53.2% when four or more LNs were positive in level I and II (P < .001). Almost 50% of patients with high level I and II nodal burden run the risk of having residual disease in the axilla after surgery if level III is not addressed. In a similar study from Turkey, 31% of the 86 patients undergoing a mastectomy had positive level III lymph nodes.14 Other studies have found level III LN positivity ranging from 15% to 59%.25,26 Skip metastases to level III ALNs are documented to occur in 0% to 15% of patients; we found the rate of skip metastases to level III ALNs to be 15.9% (95% CI, 12.5% to 19.3%).
metastases to be 0.7%. In our study, four or more ALNs in level I and II, inner/central quadrant tumor location, poor histologic grade, and presence of PNE and LVI were associated with higher level III ALN positivity. Few studies have tried to demonstrate the correlation between level III positivity and other clinicopathologic factors. In a study by Chua et al, 320 patients were evaluated. Involvement of lymph nodes in level III was observed in 22 patients (7%), and 51 patients (16%) had four or more positive nodes. Palpability of ALNs, pathologic tumor size, and LVI were significantly associated with level III involvement and four or more positive nodes by univariate and multivariate analyses. Up to 42% of patients had involved level III ALNs when four or more ALNs were positive, similar to the 53.2% seen in our study. Khafagy et al reported that 53.5% of patients had level III ALN involvement when a lower level had nodal metastases. Veronesi et al also reported an incremental risk of level III involvement with increasing number of positive lower-level nodes. The level III involvement was 8%, 25.3%, and 65.8%, respectively, when 1, 2, and 4 or more ALNs were positive in level I. In another study from China by Fan et al, the incidence of residual positive nodal disease in level III was 9% (47 of 521), even after preoperative neoadjuvant chemotherapy in stage I and II breast cancer. They showed a significantly worse distant DFS when level III ALNs were involved (84.9% and 91.6%)

| Category       | No. of Events | Survival | HR   | P     | HR   | 95% CI  | P     |
|----------------|--------------|----------|------|-------|------|---------|-------|
| Age, years     |              |          |      |       |      |         |       |
| < 50           | 148 of 815   | 81.8     | 0.89 | .34   | 1.022| 0.752 to 1.388 | .892  |
| > 50           | 105 of 775   | 86.5     |      |       |      |         |       |
| Tumor size, cm|              |          |      |       |      |         |       |
| < 5            | 216 of 1,413 | 84.7     | 1.68 | .008  | 0.625| 0.402 to 0.972 | .037  |
| ≥ 5            | 30 of 143    | 79       |      |       |      |         |       |
| Histologic grade|            |          |      |       |      |         |       |
| Grade 1, 2     | 24 of 301    | 92       | 2.67 | < .001| 2.125| 1.239 to 3.644 | .006  |
| Grade 3        | 228 of 1,278 | 82.2     |      |       |      |         |       |
| Tumor quadrant |              |          |      |       |      |         |       |
| Outer          | 109 of 761   | 85       | 1.16 | .27   | 1.060| 0.786 to 1.429 | .703  |
| Inner, central | 119 of 730   | 83.7     |      |       |      |         |       |
| No. of positive ALN |     |          |      |       |      |         |       |
| < 4            | 101 of 942   | 89.3     | 2.39 | < .001| 2.021| 1.411 to 2.895 | .000  |
| ≥ 4            | 152 of 648   | 76.5     |      |       |      |         |       |
| HER2 status    |              |          |      |       |      |         |       |
| Positive       | 66 of 343    | 80.8     | 1.5  | .007  | 1.059| 0.757 to 1.483 | .736  |
| Negative       | 151 of 1,014 | 85.1     |      |       |      |         |       |
| HR (ER and/or PR) status | | | | | | | |
| Positive       | 140 of 1,070 | 86.9     | 2.24 | < .001| 1.816| 1.323 to 2.493 | .000  |
| Negative       | 109 of 485   | 77.5     |      |       |      |         |       |
| PNE            |              |          |      |       |      |         |       |
| Absent         | 29 of 334    | 91.3     | 2.41 | < .001| 1.519| 0.931 to 2.480 | .094  |
| Present        | 218 of 1,196 | 81.8     |      |       |      |         |       |
| LVI            |              |          |      |       |      |         |       |
| Absent         | 151 of 1,025 | 85.3     | 1.34 | .028  | 1.041| 0.763 to 1.420 | .802  |
| Present        | 93 of 521    | 82.1     |      |       |      |         |       |
| Level III ALN  |              |          |      |       |      |         |       |
| Negative       | 149 of 1,157 | 87.1     | 2.26 | < .001| 1.304| 0.918 to 1.851 | .138  |
| Positive       | 104 of 433   | 76.0     |      |       |      |         |       |

Abbreviations: ALN, axillary lymph node; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; LVI, lymphovascular invasion; PNE, perinodal extension; PR, progesterone receptor.
In level III positive and negative groups, respectively; \( P = .011 \).

We found overall interpectoral node positivity to be 4.6%. If a node was found on histopathology, it was positive 38.4% of the time. Other studies have shown interpectoral node positivity ranging from 0.1% to 14%.²⁵,³⁰,³¹

Involvement of level III ALNs is a poor prognostic factor in our study. Patients with level III ALN involvement had a worse DFS (87.1% \( v \) 76%; \( P < .001 \)). Previous studies have shown a similar worse survival outcome with involvement of level III nodes.¹⁷,³² Our study is the largest prospective series addressing separate level III ALN dissection in a node-positive axilla. However, one of the main shortcomings of our study is the impact of level III dissection on survival; we cannot comment on this, because we do not have an arm for comparison where axillary level III dissection was not carried out. This was studied in a randomized manner in two studies from Japan. Tominaga et al⁶ divided 1,209 patients undergoing mastectomy for early breast cancer to axillary clearance up to level II or resection of pectoralis minor muscle and axillary dissection up to level III. The 10-year DFS rates were 73.3% and 77.8%, respectively (HR, 0.94; \( P = .666 \)). In another trial by Kodama et al,³³ 514 patients were divided to undergo either level I or level I to III axillary dissection. There were no significant differences in the 10-year overall and DFS rates in the two groups. The authors concluded that compared with exclusive level I clearance, level III dissection resulted in a longer operation time and greater blood loss but did not improve the survival rate. The disadvantage of these two studies is that they included both node-negative and node-positive patients together, potentially diluting the benefit of a complete axillary clearance in node-positive patients. Hence, the impact of level III clearance in node-positive axilla has never been studied in a systematic manner, and it is unlikely that there will now be a randomized study in this setting. We have previously described an interpectoral approach to perform a level III lymph node dissection by retracting the pectoralis minor muscle laterally.³⁴ The surgical time as well as blood loss, nerve injury, and vascular injury have been minimal with our technique. We had previously published an analysis of 148 patients who underwent revision surgery for incompletely performed initial breast resections elsewhere. One hundred twenty-three out of 148 patients (83.1%) had residual disease in the axilla, and 64 (52.03%) had positive ALNs.³⁵ This could potentially have an impact on survival as well. An RO surgical resection is currently the most standard method of achieving optimal local control of disease in breast cancer. Adjuvant radiation is an adjunct to complete surgical clearance for better locoregional outcomes and for overall survival.²¹ We emphasize the role of complete surgical resection in breast cancer, especially in a lower middle-income country like ours, where the stage at presentation and the incidence of axillary nodal metastases is high.

Surgical resection is the mainstay of treatment of non-metastatic breast cancer, and a complete surgical resection is necessary for optimal local control. In a lower-middle income country like India, there is a higher stage at presentation and a higher incidence of axillary nodal involvement. We recommend a routine axillary clearance up to level III in node-positive axilla, especially when multiple lower-level axillary nodes are involved. Intraoperative interpectoral space palpation with clearance should be considered in the presence of either palpable interpectoral lymph nodes or multiple positive ALNs.

AFFILIATION
¹Tata Memorial Hospital Parel, Mumbai, Maharashtra, India

CORRESPONDING AUTHOR
Shalaka Joshi, MS, MCh, MRes, Tata Memorial Hospital and Homi Bhabha National Institute (HBNI), Department of Surgical Oncology, Dr E Borges Road, Parel, Mumbai, Maharashtra, India; e-mail: drjoshialaka@gmail.com.

AUTHOR CONTRIBUTIONS
Conception and design: Shalaka Joshi, Vani Parmar, Nita Nair, Rajendra Badwe
Financial support: Rajendra Badwe
Administrative support: Rohini Hawaldar, Vaibhav Vannali, Tanuja Shet, Rajendra Badwe
Provision of study material or patients: Shalaka Joshi, Nita Nair, Vani Parmar, Rajendra Badwe

Collection and assembly of data: Shalaka Joshi, Jarin Noronha, Girish Kundigulwar, Vaibhav Vannali
Data analysis and interpretation: Shalaka Joshi, Jarin Noronha, Rohini Hawaldar, Girish Kundigulwar, Vani Parmar, Nita Nair, Tanuja Shet, Rajendra Badwe

Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST AND DATA AVAILABILITY STATEMENT
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution, Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

No potential conflicts of interest were reported.
REFERENCES

1. Fisher B, Montague E, Redmond C, et al: Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial. Cancer 39:2827-2839, 1977 (suppl 6)
2. Parma V, Hawaldar R, Nair NS, et al: Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer. Breast 22:1081-1086, 2013
3. Krag DN, Anderson SJ, Julian TB, et al: Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927-933, 2010
4. Pesek S, Ashikaga T, Krag LE, et al: The false-negative rate of sentinel lymph node biopsy in patients with breast cancer: A meta-analysis. World J Surg 36:2239-2251, 2012
5. Ashikaga T, Krag DN, Land SR, et al: Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 102:111-118, 2010
6. National Comprehensive Cancer Network: NCCN Guidelines for the Treatment of Breast Cancer. 2017 https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
7. Giuliano AE, McCall LM, Bieitsch PD, et al: ACOSOG Z0011: A randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 28, 2010 (suppl; abstr CRA506)
8. Donker M, van Tienhoven G, Straver ME, et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303-1310, 2014
9. Tominaiga T, Takashima S, Danno M: Randomized clinical trial comparing level II and level III axillary node dissection in addition to mastectomy for breast cancer. Br J Surg 91:38-43, 2004
10. Black DM, Mittendorf EA: Landmark trials affecting the surgical management of invasive breast cancer. Surg Clin North Am 93:501-518, 2013
11. Fisher B, Redmond C, Fisher ER, et al: Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 312:674-681, 1985
12. Veronesi U, Paganelli G, Viale G, et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546-553, 2003
13. Kiricuta C, Taubes J: A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 69:2496-2501, 1992
14. Adlan S: Level III lymph node involvement in breast carcinoma. Turkish Journal of Cancer. 37:109-113, 2007
15. Mansel RE, Fallowfield L, Kissin M, et al: Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst 98:599-609, 2006
16. Krag DN, Anderson SJ, Julian TB, et al: Technical outcomes of sentinel-lymph-node resection compared with routine axillary lymph-node dissection in patients with clinically node-negative breast cancer: Results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8:881-888, 2007
17. Kuru B, Camlibel M, Dinc S, et al: Prognostic significance of axillary node and infraclavicular lymph node status after mastectomy. Eur J Surg Oncol 29:839-844, 2003
18. Fisher B, Wolmark N, Redmond C, et al: Findings from NSABP Protocol No. B-04: Comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer 48:1863-1872, 1981
19. Axelson CK, Mounitsen HT, Zedeler K: Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Collaborative Group (DBC). Eur J Cancer 28A:1415-1418, 1992
20. Orr RK: The impact of prophylactic axillary node dissection on breast cancer survival—A Bayesian meta-analysis. Ann Surg Oncol 6:109-116, 1999
21. EBCTCG (Early Breast Cancer Trialists' Collaborative Group), McGale P, Taylor C, et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383:2127-2135, 2014
22. Lin PP, Allison DC, Wainstock J, et al: Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 11:1536-1544, 1993
23. Kim T, Giuliano AE, Lyman GH: Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: A metaanalysis. Cancer 106:4-16, 2003
24. Bromham N, Schmidt-Hansen M, Astin M, et al: Axillary treatment for operable primary breast cancer. Cochrane Database Syst Rev 1:CD004561, 2017
25. Khafagy M, Mostafa A, Fakhr I, et al: Distribution of axillary lymph node metastases in different levels and groups in breast cancer: A pathological study. J Egypt Natl Canc Inst 23:25-30, 2011
26. Veronesi U, Rilke F, Luini A, et al: Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 59:682-687, 1987
27. Rosen PP, Lesser ML, Kinne DW, et al: Discontinuous or "skip" metastases in breast carcinoma. Analysis of 1228 axillary dissections. Ann Surg 197:276-283, 1983
28. Chua B, Uong O, Taylor R, et al: Is there a role for axillary dissection for patients with operable breast cancer in this era of conservatism? ANZ J Surg 72:786-792, 2002
29. Fan Z, Li J, Wang T, et al: Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy. Breast 22:1161-1165, 2013
30. Bale A, Gardner B, Shende M, et al: Can interpectoral nodes be sentinel nodes? Am J Surg 178:360-361, 1999
31. Ouyang T, Li JF, Wang TF, et al: Exploration of the extent of axillary dissection for patients with node positive primary breast cancer (in Chinese). Zhonghua Wai Ke Za Zhi 43:298-300, 2005
32. Veronesi U, Galimberti V, Zurrida S, et al: Prognostic significance of number and level of axillary node metastases in breast cancer. Breast 2:224-228, 1993
33. Kodama H, Nio Y, Iuchi C, et al: Ten-year follow-up results of a randomised controlled study comparing level-I vs level-III axillary lymph node dissection for primary breast cancer. Br J Cancer 95:811-816, 2006
34. Pai A, Gupta P, Raina S, et al: Interpectoral approach to dissection of the axillary apex: An elegant and effective approach. J Surg Oncol 94:252-254, 2006
35. Thorat MA, Rangole A, Nadkarni MS, et al: Revision surgery for breast cancer: Single-institution experience. Cancer 113:2347-2352, 2008 (suppl 8)